For instance, in the SURPASS-4 trial, where tirzepatide was compared with insulin glargine in patients with T2DM and a high cardiovascular risk, 15 mg of tirzepatide reduced the levels of TC, LDL-C, and TGs by 5.6%, 7.9%, and 22.5%, respectively, and increased the levels of HDL-C by 10.8%.5 In the SURPASS-5 trial, where tirzepatide was added to basal insulin treatment, tirzepatide also showed favorable effects on lipid profile parameters compared with placebo in patients with T2DM.6 Specifically, tirzepatide reduced the levels of TC, LDL-C, and TGs by 12.9%, 15.5%, and 24.9%, respectively, and increased the levels of HDL-C by 0.9%.6 In both trials, the effects of tirzepatide on lipid profile were dose-dependent, with greater improvements observed at higher doses and these improvements were sustained over the duration of the trials.5, 6 Table 1 summarizes the main findings of the SURPASS programs regarding the ability of tirzepatide to improve atherogenic dyslipidemia
2.4.2 HPSE Heparinase (HPSE) is an endonucleating -D-glucuronidase that interacts with TGF- to modulate the remodeling and degradation of the ECM, and the release of various cytokines (Rabelink et al., 2017)
Consulting with a healthcare provider can help mitigate these risks
More GLP-1 Drugs on the Way No drug company wants to miss out on GLP-1 bonanza and more drugs are on the way
